For this reason, p38 plays a fundamental role in the approach to conventional cancer therapies, such as radiotherapy or chemotherapy and targeted treatments, using certain small molecules that act as inhibitors of key steps in the signaling pathway, although they can induce resistance from the first dose due to the positive selection of those tumor cells that are able to compensate the specific target pathway. Here, MAPK14 is linked to neoplasm.